LV10923B - Derivates of penciclovir for the treatment of hepatitis- b infections - Google Patents
Derivates of penciclovir for the treatment of hepatitis- b infections Download PDFInfo
- Publication number
- LV10923B LV10923B LVP-95-253A LV950253A LV10923B LV 10923 B LV10923 B LV 10923B LV 950253 A LV950253 A LV 950253A LV 10923 B LV10923 B LV 10923B
- Authority
- LV
- Latvia
- Prior art keywords
- compound
- formula
- use according
- hepatitis
- treatment
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 10
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 title claims description 6
- 229960001179 penciclovir Drugs 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 125000002252 acyl group Chemical group 0.000 claims abstract description 9
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 6
- 239000010452 phosphate Substances 0.000 claims abstract description 6
- -1 phosphate ester Chemical class 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 10
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Chemical group 0.000 claims description 6
- 239000001257 hydrogen Chemical group 0.000 claims description 6
- 229960004396 famciclovir Drugs 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 abstract description 12
- 239000000651 prodrug Substances 0.000 abstract description 12
- 239000003981 vehicle Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
- LV 10923 IZGUDROJUMA FORMULA 1. Savienojuma ar formulu (A)HO-CH2-CH-CH2-OH (A) vai tā medikamenta priekšteča, vai farmaceitiski saderīga sāls, fosfāta estera un/vai acilatvasinājuma - jebkura no iepriekšminētajiem - pielietošana medikamenta iegūšanai, kurus lieto hepatīta-B vīrusa infekciju ārstēšanai.
- 2. Pielietošana saskaņā ar 1. punktu, kas atšķiras ar to, ka šis savienojums ir penciklovīrs ar formulu (A).
- 3. Pielietošana saskaņā ar 1. punktu, kas atšķiras ar to, ka šis savienojums ir savienojuma ar formulu (A) nātrija sāls hidrāts.
- 4. Pielietošana saskaņā ar 3. punktu, kas atšķiras ar to, ka medikaments ir ūdenī šķīstošā formā, kas piemērota parenterālai ievadīšanai.
- 5. Pielietošana saskaņā ar 1. punktu, kas atšķiras ar to, ka savienojums ir savienojuma ar formulu (A) medikamenta priekštecis, kurš atbilst formulai (B) X( CH2)2 ho-ch2-ch-ch2-oh ( B ) vai tā šālim vai atvasinājumam, kā norādīts 1. punktā attiecībā uz formulu (A), kur X ir C-ļ.g alkoksigrupa, NH2-grupa vai ūdeņraža atoms.
- 6. Pielietošana saskaņā ar 5. punktu, kas atšķiras ar to, ka medikamenta priekštecis ar formulu (B) ir famciklovīrs, kur X ir ūdeņraža atoms un kur divas OH-grupas ir acetilatvasinājuma formā.
- 7. Pielietošana saskaņā ar 6. punktu, kas atšķiras ar to, ka medikaments ir piemērots orālai ievadīšanai.
- 8. Pielietošana saskaņā ar 1. punktu, kas atšķiras ar to, ka savienojuma vienas devas daudzums, kas tiek ievadīts, ir no 50 mg līdz 1g.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898904855A GB8904855D0 (en) | 1989-03-03 | 1989-03-03 | Pharmaceutical treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10923A LV10923A (lv) | 1995-12-20 |
| LV10923B true LV10923B (en) | 1996-06-20 |
Family
ID=10652653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-95-253A LV10923B (en) | 1989-03-03 | 1995-08-16 | Derivates of penciclovir for the treatment of hepatitis- b infections |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6136813A (lv) |
| EP (1) | EP0388049B1 (lv) |
| JP (1) | JP2513519B2 (lv) |
| KR (1) | KR0143410B1 (lv) |
| AT (1) | ATE122562T1 (lv) |
| AU (1) | AU628137B2 (lv) |
| CA (1) | CA2011238C (lv) |
| CY (1) | CY1870A (lv) |
| DE (1) | DE69019404T2 (lv) |
| DK (1) | DK0388049T3 (lv) |
| ES (1) | ES2072386T3 (lv) |
| GB (1) | GB8904855D0 (lv) |
| HK (1) | HK116795A (lv) |
| HU (1) | HU205715B (lv) |
| IE (1) | IE67125B1 (lv) |
| IL (1) | IL93594A (lv) |
| LV (1) | LV10923B (lv) |
| ZA (1) | ZA901572B (lv) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326177D0 (en) * | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Pharmaceuticals |
| US6124304A (en) * | 1993-10-05 | 2000-09-26 | Smithkline Beecham Plc | Penciclovir for the treatment of zoster associated pain |
| WO1995022330A1 (en) * | 1994-02-17 | 1995-08-24 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| US7045525B1 (en) | 1995-04-24 | 2006-05-16 | Novartis Ag | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases |
| WO1998023285A1 (en) * | 1996-11-29 | 1998-06-04 | Smithkline Beecham Plc | Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b |
| US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| AUPO912997A0 (en) * | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| US6288033B1 (en) | 1998-09-25 | 2001-09-11 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir |
| DK1382343T3 (da) * | 1998-11-02 | 2010-04-26 | Gilead Sciences Inc | Kombinationsterapi til behandling af hepatitis B-virus |
| WO2013167743A1 (en) | 2012-05-11 | 2013-11-14 | Akron Molecules Gmbh | Use of compounds for the treatment of pain |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4199574A (en) * | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
| US4230708A (en) * | 1977-10-20 | 1980-10-28 | Stichting Rega V.Z.W. | Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents |
| NL8202626A (nl) * | 1982-06-29 | 1984-01-16 | Stichting Rega V Z W | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
| US4556659A (en) * | 1982-08-09 | 1985-12-03 | Syntex (U.S.A.) Inc. | Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-Di-0-substituted propoxymethyl)-purines as antiviral agents |
| US5059604A (en) * | 1982-10-14 | 1991-10-22 | Burroughs Wellcome Co. | 2-amino purine derivatives |
| US4649140A (en) * | 1982-10-14 | 1987-03-10 | Burroughs Wellcome Co. | Purine derivatives |
| DE3485225D1 (de) * | 1983-08-18 | 1991-12-05 | Beecham Group Plc | Antivirale guanin-derivate. |
| IL73682A (en) * | 1983-12-20 | 1991-08-16 | Medivir Ab | Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation |
| DE3582399D1 (de) * | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
| SE8406538D0 (sv) * | 1984-12-21 | 1984-12-21 | Astra Laekemedel Ab | Novel derivatives of purine |
| EP0216459B1 (en) * | 1985-07-27 | 1990-05-16 | Beecham Group Plc | 9-substituted guanine monohydrates |
| SE8602981D0 (sv) * | 1986-07-04 | 1986-07-04 | Astra Laekemedel Ab | Novel medicinal use |
| HU196038B (en) * | 1987-08-07 | 1988-09-28 | Mta Koezponti Kemiai Kutato In | Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine |
| SE8801729D0 (sv) * | 1988-05-06 | 1988-05-06 | Astra Ab | Purine derivatives for use in therapy |
| GB8823320D0 (en) * | 1988-10-05 | 1988-11-09 | Nycomed As | Chemical compounds |
-
1989
- 1989-03-03 GB GB898904855A patent/GB8904855D0/en active Pending
-
1990
- 1990-03-01 ES ES90302186T patent/ES2072386T3/es not_active Expired - Lifetime
- 1990-03-01 AT AT90302186T patent/ATE122562T1/de not_active IP Right Cessation
- 1990-03-01 HU HU901252A patent/HU205715B/hu unknown
- 1990-03-01 AU AU50600/90A patent/AU628137B2/en not_active Expired
- 1990-03-01 EP EP90302186A patent/EP0388049B1/en not_active Expired - Lifetime
- 1990-03-01 DE DE69019404T patent/DE69019404T2/de not_active Expired - Lifetime
- 1990-03-01 ZA ZA901572A patent/ZA901572B/xx unknown
- 1990-03-01 IE IE73390A patent/IE67125B1/en not_active IP Right Cessation
- 1990-03-01 DK DK90302186.3T patent/DK0388049T3/da active
- 1990-03-01 CA CA002011238A patent/CA2011238C/en not_active Expired - Lifetime
- 1990-03-01 IL IL9359490A patent/IL93594A/en not_active IP Right Cessation
- 1990-03-02 JP JP2049722A patent/JP2513519B2/ja not_active Expired - Lifetime
- 1990-03-03 KR KR1019900002767A patent/KR0143410B1/ko not_active Expired - Fee Related
-
1994
- 1994-08-08 US US08/287,476 patent/US6136813A/en not_active Expired - Lifetime
-
1995
- 1995-07-13 HK HK116795A patent/HK116795A/en not_active IP Right Cessation
- 1995-08-16 LV LVP-95-253A patent/LV10923B/en unknown
-
1996
- 1996-04-05 CY CY187096A patent/CY1870A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2011238A1 (en) | 1990-09-03 |
| LV10923A (lv) | 1995-12-20 |
| HU901252D0 (en) | 1990-05-28 |
| IL93594A0 (en) | 1990-12-23 |
| HU205715B (en) | 1992-06-29 |
| GB8904855D0 (en) | 1989-04-12 |
| JP2513519B2 (ja) | 1996-07-03 |
| EP0388049A3 (en) | 1991-11-06 |
| DK0388049T3 (da) | 1995-06-06 |
| EP0388049A2 (en) | 1990-09-19 |
| CY1870A (en) | 1996-04-05 |
| AU5060090A (en) | 1990-11-01 |
| IE900733L (en) | 1990-09-03 |
| DE69019404D1 (de) | 1995-06-22 |
| ZA901572B (en) | 1991-03-27 |
| DE69019404T2 (de) | 1995-10-12 |
| AU628137B2 (en) | 1992-09-10 |
| HK116795A (en) | 1995-07-21 |
| ES2072386T3 (es) | 1995-07-16 |
| IL93594A (en) | 1995-05-26 |
| ATE122562T1 (de) | 1995-06-15 |
| KR0143410B1 (ko) | 1998-07-15 |
| HUT53522A (en) | 1990-11-28 |
| US6136813A (en) | 2000-10-24 |
| JPH02275821A (ja) | 1990-11-09 |
| EP0388049B1 (en) | 1995-05-17 |
| CA2011238C (en) | 2000-03-28 |
| IE67125B1 (en) | 1996-03-06 |
| KR900014385A (ko) | 1990-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU226778B1 (en) | Injection and injection kit containing omeprazole and its analogs | |
| LV10923B (en) | Derivates of penciclovir for the treatment of hepatitis- b infections | |
| CA2086756C (en) | Penciclovir and famciclovir and related guanine derivatives for the treatment of the hiv-1 infections | |
| KR960014991B1 (ko) | 2',3'-디데옥시시티딘을 극히 저용량으로 함유하는 약제학적 조성물 | |
| US5840763A (en) | Treatment of a latent infection of herpes viruses | |
| EP0814813B1 (en) | Use of penciclovir for the treatment of human herpes-virus-8 | |
| EP0728002B1 (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection | |
| US5674869A (en) | Pharmaceutical treatment | |
| US6057327A (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections | |
| CN1084622C (zh) | 药物 | |
| KR100382707B1 (ko) | 잠재적허피스바이러스감염의치료및예방을위한아미노퓨린항바이러스제의용도 | |
| RU2293562C2 (ru) | Использование аминопуриновых противовирусных соединений для лечения и профилактики латентных инфекций, вызванных вирусом герпеса | |
| JPH06227982A (ja) | 抗ウイルス剤 | |
| HK1004373B (en) | Use of penciclovir for the treatment of human herpes-virus-8 | |
| HK1012233B (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections | |
| MXPA97004336A (en) | Use of antiviral agents for the treatment and prophylaxis of latent infections of herpesvi |